The test is covered for serial use in patients with colorectal cancer in the adjuvant and recurrence monitoring settings over a five-year period.

The firms will distribute NowDx's First to Know test to more than 15 organizations nationwide, including LGBTQ+ health centers, HIV/AIDS care providers, and safety net clinics.

The acquisition was opposed by some Quanterix shareholders. In May, Akoya also said it received an unsolicited acquisition bid for the firm.

NEW YORK – A federal judge on Tuesday ruled that the US Department of Health and Human Services' March decision to lay off 10,000 staff members as part of a major restructuring was likely unlawful and ...